calendar
3,924 catalysts · 3,827 phase readout · 2,118 8k filing · 276 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage
3,924 catalysts · 3,827 phase readout · 2,118 8k filing · 276 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage
Sponsor: AUROBINDO PHARMA LTD. Form: SUSPENSION, EXTENDED RELEASE. Route: ORAL
Sponsor: BIOCODEX SA. Form: FOR SUSPENSION. Route: ORAL
Sponsor: MYLAN LABS LTD. Form: INJECTABLE. Route: INTRAVENOUS
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
Sponsor: EDENBRIDGE PHARMS. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: OXFORD PHARMS. Form: TABLET. Route: ORAL
Sponsor: IMPAX LABS. Form: TABLET. Route: ORAL
Sponsor: IMPAX LABS. Form: TABLET. Route: ORAL
Sponsor: IMPAX LABS. Form: TABLET. Route: ORAL
Sponsor: SAMSUNG BIOEPIS CO LTD. Form: POWDER. Route: IV (INFUSION)
Sponsor: BAXTER HLTHCARE CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: GE HLTHCARE INC. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: GENENTECH INC. Form: TABLET. Route: ORAL
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL
Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain
Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain
Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder